Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03798626
Title	Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Novartis Pharmaceuticals
Indications	renal cell carcinoma colorectal cancer gastroesophageal cancer
Therapies	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| ISR \| GBR \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS